Abstract
We conducted a prospective, naturalistic study to assess the offer and acceptance of p-tau217 in capable patients with cognitive symptoms and possible Alzheimer's disease (AD). p-tau217 was offered to 170/221 (76.9%) eligible patients, of whom 126 (74.1%) accepted. Competing medical priorities (31.4%) and personal decision (59.1%) were the most frequent causes for not offering or rejecting the study, respectively. As neurologists gained experience using p-tau217, both offering (OR 2.19 [CI 95% 1.14–4.19]) and acceptance (OR 2.71 [CI 95% 1.33–5.53]) increased. p-tau217 should be offered by experienced clinicians, after considering patient's comorbidity, psychological, and social circumstances. Clear patient decision is mandatory.
Get full access to this article
View all access options for this article.